[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394888":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":51,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Medical University of Graz","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Thrombelastogram (TEG)","EXPERIMENTAL","Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE\u002Fkg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.",[13],"Procedure: thrombelastogram",{"label":15,"type":10,"description":16,"interventionNames":17},"Standard of Care (SOC)","In the SOC group, patients will receive PCC at the dose of 10 IE \u002Fkg of ideal body weight when the PT is below 50% and\u002For INR\\>1.8 and\u002For received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G\u002FL",[18],"Procedure: standard of care",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","thrombelastogram","Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE\u002Fkg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"standard of care","2\\) In the SOC group, patients will receive PCC at the dose of 10 IE \u002Fkg of ideal body weight when the PT is below 50% and\u002For INR\\>1.8 and\u002For received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G\u002FL",[15],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Internal Medicine, Medical University of Graz","RECRUITING","Graz","8010","Austria","AT",{"type":39,"coordinates":40},"Point",[41,42],15.44197,47.06733,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Vanessa Stadlbauer, MD","CONTACT","0043316385","82282","vanessa.stadlbauer@medunigraz.at",{"type":52,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100394888","periinterventional-coagulation-management-of-patients-undergoing-a-tips-100394888",false,"NCT04421924","Periinterventional Coagulation Management of Patients Undergoing a TIPS","Optimizing Periinterventional Coagulation Management of Patients Undergoing a Transjugular Intrahepatic Portosystemic Shunt Implantation: A Prospective Randomized Cohort Study","TIPSprosp","inclusion criteria\n\n* Liver cirrhosis\n* \\>18 years\n* Indication for TIPS implantation\n* Ability to sign informed consent exclusion criteria\n* Contraindications against TIPS implantation\n* Hepatocellular carcinoma BCLC D\n* Ongoing bleeding\n* pre-existing anticoagulant therapy at time of inclusion\n* administration of blood products within 1 week prior to the enrolment\n* Other malignancies that lead to an impaired 90-day survival\n* Inherit blood clotting disorders\n* Hepatic encephalopathy grade 3 or 4\n* any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol","ALL","18 Years",{"count":64,"type":65},39,"ESTIMATED","INTERVENTIONAL",[68],"NA","Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective",[71],"Liver Cirrhosis","2025-12-02",{"date":74,"type":75},"2025-12-09","ACTUAL",{"date":77,"type":75},"2020-05-27",{"date":79,"type":65},"2027-05",{"name":5,"class":6},1]